These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6913237)

  • 21. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs can trigger pathological gambling.
    Prescrire Int; 2002 Feb; 11(57):16. PubMed ID: 11985369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3-normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons.
    Summers MY; Leighton M; Liu D; Pong K; Graziani EI
    J Antibiot (Tokyo); 2006 Mar; 59(3):184-9. PubMed ID: 16724459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Othello syndrome in Parkinson disease patients without dementia.
    Cannas A; Solla P; Floris G; Tacconi P; Marrosu F; Marrosu MG
    Neurologist; 2009 Jan; 15(1):34-6. PubMed ID: 19131855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
    Takashima H; Tsujihata M; Kishikawa M; Freed WJ
    Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anticholinergic anti-Parkinson agents].
    Taurand S
    Soins; 1996 Apr; (605):61-2. PubMed ID: 8716255
    [No Abstract]   [Full Text] [Related]  

  • 28. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
    Schapira AH
    Mov Disord; 2008; 23 Suppl 3():S515-20. PubMed ID: 18781678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ropinirole in the treatment of Parkinson's disease: an update].
    Vivancos-Matellano F
    Rev Neurol; 2006 May 1-15; 42(9):542-8. PubMed ID: 16676278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
    Rascol O
    Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The midbrain slice preparation. An in vitro model to select potential anti-parkinsonian drugs?
    Guatteo E; Cucchiaroni ML; Sebastianelli L; Bernardi G; Mercuri NB
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S150-3. PubMed ID: 18583176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A survey of antipsychotic treatment for schizophrenia in Hong Kong.
    Yip KC; Ungvari GS; Cheung HK; Ng FS; Lau ST
    Chin Med J (Engl); 1997 Oct; 110(10):792-6. PubMed ID: 9642312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to antiparkinson medication in a multicenter European study.
    Grosset D; Antonini A; Canesi M; Pezzoli G; Lees A; Shaw K; Cubo E; Martinez-Martin P; Rascol O; Negre-Pages L; Senard A; Schwarz J; Strecker K; Reichmann H; Storch A; Löhle M; Stocchi F; Grosset K
    Mov Disord; 2009 Apr; 24(6):826-32. PubMed ID: 19191340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.